Elabela vs Vasostatin — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
Elabela (also called Apela or Toddler) is the second endogenous peptide ligand for the APJ receptor, discovered in 2013 independently through two approaches: as an essential zebrafish cardiac development factor (Toddler) and as a novel human APJ ligand (Elabela). Unlike apelin pe...
Calculate Elabela dose →Vasostatin refers to the N-terminal fragments of chromogranin A (CgA), particularly CgA1-76 (Vasostatin-1) and CgA1-113 (Vasostatin-2), generated by proteolytic processing of the chromogranin A precursor. While catestatin (CgA352-372) is the C-terminal CgA fragment with anti-cate...
Calculate Vasostatin dose →| Parameter | Elabela | Vasostatin |
|---|---|---|
| Category | Cardiovascular Peptide | Cardiovascular Peptide |
| Research | Research | Preclinical Research |
| Half-Life | Short (minutes, estimated) | ~20-30 minutes (estimated) |
| Typical Dose | 5-500 nmol/kg (animal) | 0.1-10 nmol/kg IV (animal) |
| Frequency | Variable | Acute dosing |
| Route | Subcutaneous, Intravenous | IV (research) |
| FDA Status | Not approved | Research compound |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.